FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Nootropic Focus Stack

Cognitive Enhancementbeginner
41
Share
Pépétides

2

Moyenne journalière en mcg

900

Niveau

beginner

Ajouté

May 16, 2026

Aperçu

The Nootropic Focus Stack is a beginner-friendly cognitive enhancement protocol combining two closely related Russian-developed neuropeptides that target complementary aspects of brain function. Selank, an anxiolytic heptapeptide based on the natural immunomodulator tuftsin, pairs with Semax, a synthetic analog of adrenocorticotropic hormone (ACTH 4-10), to deliver comprehensive cognitive optimization spanning focus, memory, mood stability, and mental clarity. Selank at 300mcg daily functions primarily as an anxiolytic and mood stabilizer by modulating GABAergic transmission, stabilizing enkephalin degradation, and influencing serotonin and dopamine metabolism. It reduces anxiety and mental noise without sedation or cognitive dulling, effectively clearing the emotional interference that degrades concentration and working memory. Research demonstrates its ability to enhance memory consolidation under stress and promote a calm, focused mental state conducive to sustained intellectual work. Semax at 600mcg daily is a potent nootropic that increases brain-derived neurotrophic factor (BDNF) expression, enhances attention and information processing, improves memory formation and recall, and provides neuroprotective effects against oxidative stress. It works through melanocortin receptor modulation and has been shown to increase cerebral blood flow and neural plasticity. Unlike stimulant-based cognitive enhancers, Semax does not cause jitteriness, tolerance buildup, or crash. The synergy between these peptides is particularly elegant: Selank removes the anxiety and mental fragmentation that impedes cognitive performance while Semax actively enhances the underlying neural machinery for learning, attention, and memory. Together, they create a state of calm, sustained focus that many users describe as their cognitive ideal. Both peptides are typically administered intranasally for rapid absorption and direct CNS access. Take Selank in the morning or before cognitively demanding work. Semax can be split into two doses (morning and early afternoon) or taken as a single morning dose. Avoid evening administration of Semax as it may interfere with sleep onset in some individuals. This stack is ideal for students, knowledge workers, creative professionals, and anyone seeking enhanced mental performance without the side effects of traditional stimulants. It is well-suited for those experiencing brain fog, difficulty concentrating, or stress-related cognitive decline. Both peptides have extensive clinical use in Russia with strong safety profiles. Cycle 4-8 weeks on, 2-4 weeks off, though some users report sustained benefits with longer continuous use.

Protocole de dose

300 mcg

par dose

600 mcg

par dose

Objectifs & Preuves

Niveau d'évidence :community

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.